Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. by Rebmann, V, Schütt, P, Brandhorst, D, Opalka, B, Moritz, T, Nowrousian, MR, Grosse-Wilde, H

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment. by Schütt, P, Buttkereit, U, Brandhorst, D, Lindemann, M, Schmiedl, S, Grosse-Wilde, H, Seeber, S, Nowrousian, MR, Opalka, B, Moritz, T

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients. by Schütt, P, Rebmann, V, Brandhorst, D, Wiefelspütz, J, Ebeling, P, Opalka, B, Seeber, S, Nowrousian, MR, Moritz, T, Grosse-Wilde, H

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections. by Schütt, P, Brandhorst, D, Stellberg, W, Poser, M, Ebeling, P, Müller, S, Buttkereit, U, Opalka, B, Lindemann, M, Grosse-Wilde, H, Seeber, S, Moritz, T, Nowrousian, MR